Business
Adia Nutrition, Inc. Looking to Acquire Larger Property to Expand Flagship Clinic in Winter Park, Reports Strong Operational Momentum in Q1 2026 and Provides Optimistic Outlook for Remainder of the Year
Winter Park, Florida--(Newsfile Corp. - April 22, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and biologic products through its Adia Med clinics and Adia Labs division, today announced that it is actively looking to acquire a larger property to expand its flagship Adia Med clinic in Winter Park, Florida. This strategic initiative aims to significantly increase the clinic's size and capacity, enabling expanded patient access to advanced...
About this update from Adia Nutrition, Inc.
[{"type":"text","content":"Winter Park, Florida--(Newsfile Corp. - April 22, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and biologic products through its Adia Med clinics and Adia Labs division, today announced that it is actively looking to acquire a larger property to expand its flagship Adia Med clinic in Winter Park, Florida. This strategic initiative aims to significantly increase the clinic's size and capacity, enabling expanded patient access to advanced regenerative treatments, additional Stem Cell research capabilities, and support for future growth.","length":599,"tagName":"p"},{"type":"text","content":"The potential acquisition would represent an important step in scaling operations to meet growing demand for AdiaVita (umbilical cord blood-derived stem cells and exosomes) and related therapies. The larger facility is expected to accommodate higher patient volumes, enhanced research activities, and the integration of new services, including potential insurance-billable treatments in wound care and orthopedics. This aligns with the company's ongoing efforts to expand its clinical footprint beyond the current Winter Park location.","length":539,"tagName":"p"},{"type":"text","content":"Q1 2026 HighlightsAdia Nutrition continued building momentum in the first quarter of 2026, following its strong 2025 performance in which the company reported approximately $700,508 in revenue — a substantial increase from $6,380 in 2024. This growth was driven primarily by biologic product sales (approximately 63%) and medical procedures (approximately 35%).","length":362,"tagName":"p"},{"type":"text","content":"Key operational achievements in Q1 included:","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Submission of the final revised IRB protocol for the lower back pain clinical study using AdiaVita, incorporating feedback for a single-blind, placebo-controlled trial with crossover design.","length":190,"tagName":"p"}]},{"val":[{"type":"text","content":"Progress toward initiating four to five new clinical studies throughout 2026, including expansion of the ongoing Autism Spectrum Disorder (ASD) study (treatments beginning in May 2026) and a new dedicated rheumatoid arthritis (RA) study evaluating AdiaVita's immune-modulating effects.","length":289,"tagName":"p...